EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

A Four‐Center Study on the Activity of Aztreonam and Aztreonam‐Avibactam Combination Against Clinical Isolates of Gram‐Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β‐Lactamases

Gizem İnce Ceviz, Hasan Cenk Mirza iD, Aylin Üsküdar Güçlü iD, Özlem Öğüç Şanlı, Özlem Kurt Azap, Banu Sancak iD, Elvan Hortaç İştar, Ahmet Başustaoğlu

APMIS · 2026

DOI: 10.1111/apm.70265 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift APMIS, 2026. Verfasst von Gizem İnce Ceviz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Başkent University Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Aztreonam, beta-Lactamases, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Baskent Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to investigate the activity of aztreonam and aztreonam‐avibactam combination against gram‐negative bacilli producing different types of β‐lactamases. Activity of aztreonam and aztreonam‐avibactam against 166 isolates (33 AmpC‐producing, 33 ESBL‐producing, 66 carbapenemase‐producing Enterobacterales, 34 metallo‐β‐lactamase‐producing P. aeruginosa ) from four centers in Türkiye was determined using gradient diffusion method. Aztreonam susceptibility rates among AmpC‐producing, ESBL‐producing and carbapenemase‐producing Enterobacterales were 75.8%, 3% and 6.1%, respectively. All AmpC‐producing or ESBL‐producing Enterobacterales were susceptible to aztreonam‐avibactam. ESBL‐producing K. pneumoniae had significantly higher aztreonam‐avibactam MICs compared with ESBL‐producing E. coli . K. pneumoniae carrying bla CTX ‐M + bla SHV + bla TEM had significantly higher aztreonam‐avibactam MICs when compared to those carrying only bla CTX‐M . Aztreonam‐avibactam susceptibility rate among carbapenemase‐producing K. pneumoniae (100%) was significantly higher than that observed for carbapenemase‐producing E. coli (65%). Metallo‐β‐lactamase‐producing P. aeruginosa had significantly higher aztreonam‐avibactam MICs (MIC 50/90 : 16/96 mg/L) when compared to metallo‐β‐lactamase‐producing Enterobacterales (MIC 50/90 : 0.19/8 mg/L). Aztreonam‐avibactam may be an option for treatment of infections caused by ESBL‐producing or AmpC‐producing K. pneumoniae , E. coli and carbapenemase‐producing K. pneumoniae . However, aztreonam‐avibactam resistance may be encountered in a considerable portion of carbapenem‐resistant E. coli isolates. High aztreonam‐avibactam MIC values suggest limited in vitro activity of aztreonam‐avibactam against MBL‐producing P. aeruginosa isolates in this collection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aztreonambeta-LactamasesAzabicyclo CompoundsAnti-Bacterial AgentsGram-Negative BacteriaGram-Negative Bacterial InfectionsMicrobial Sensitivity TestsHumansPseudomonas aeruginosaBacterial ProteinsDrug Combinations

Stichwörter der Autor:innen

E. coliK. pneumoniaeP. aeruginosaaztreonamaztreonam‐avibactam

Substanzen

Aztreonambeta-LactamasesAzabicyclo CompoundsAnti-Bacterial AgentsavibactamBacterial Proteinsaztreonam, avibactam drug combinationDrug Combinations

Autor:innen und Institutionen

  • Department of Medical Microbiology, Başkent University Faculty of Medicine, Ankara, Türkiye.
  • Department of Medical Microbiology, Adana Medical and Research Center, Başkent University Faculty of Medicine, Adana, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Başkent University Faculty of Medicine, Ankara, Türkiye.
  • Department of Medical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
  • Department of Medical Microbiology, Etlik City Hospital, Ankara, Türkiye.
  • Department of Medical Microbiology, Girne American University Faculty of Medicine, Kyrenia, Northern Cyprus.

ORCID-Profile: Hasan Cenk Mirza, Aylin Üsküdar Güçlü, Banu Sancak

Förderung

  • Baskent Üniversitesi

Zitieren

APA

Ceviz, G. İ., Mirza, H. C., Güçlü, A. Ü., Şanlı, Ö. Ö., Azap, Ö. K., Sancak, B., İştar, E. H., & Başustaoğlu, A. (2026). A Four‐Center Study on the Activity of Aztreonam and Aztreonam‐Avibactam Combination Against Clinical Isolates of Gram‐Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β‐Lactamases. APMIS. https://doi.org/10.1111/apm.70265

Vancouver

Ceviz Gİ, Mirza HC, Güçlü AÜ, Şanlı ÖÖ, Azap ÖK, Sancak B, et al. A Four‐Center Study on the Activity of Aztreonam and Aztreonam‐Avibactam Combination Against Clinical Isolates of Gram‐Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β‐Lactamases. APMIS. 2026. doi:10.1111/apm.70265

BibTeX
@article{Ceviz2026,
  author = {Ceviz, Gizem İnce and Mirza, Hasan Cenk and Güçlü, Aylin Üsküdar and Şanlı, Özlem Öğüç and Azap, Özlem Kurt and Sancak, Banu and İştar, Elvan Hortaç and Başustaoğlu, Ahmet},
  title = {A Four‐Center Study on the Activity of Aztreonam and Aztreonam‐Avibactam Combination Against Clinical Isolates of Gram‐Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β‐Lactamases},
  journal = {APMIS},
  year = {2026},
  doi = {10.1111/apm.70265}
}
Kostenlos starten →